Vice President, Medical Affairs Oncology

Parabilis Medicines•Cambridge, MA

1d•Onsite

About The Position

As a member of the Parabilis Medicines team, you will be a part of an organization dedicated to creating extraordinary medicines for diseases with urgent unmet needs, harnessing our proprietary peptide platform to transform treatment possibilities for patients. Parabilis is a clinical-stage biopharmaceutical company dedicated to unlocking high-impact protein targets long-considered undruggable. The company has developed a new class of stabilized, cell-penetrant alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that are inaccessible to traditional drug modalities. Headquartered in Cambridge, Mass., Parabilis is advancing a focused pipeline of multiple first-in-class therapies across both rare and common cancers. Its lead asset, zolucatetide (FOG-001), is a first-in-class, clinically validated direct inhibitor of the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors, implicated in millions of cancer cases annually, including in colorectal cancer, desmoid tumors, hepatocellular carcinoma and a range of other Wnt/β-catenin-driven tumors. In Phase 1 clinical trials, zolucatetide produced the first-ever clinical evidence that it can directly inhibit this interaction, once previously considered “undruggable” despite its role across multiple cancer types. Parabilis is also advancing investigational degraders of ERG and ARON into clinical development for the treatment of prostate cancer, as well as progressing other preclinical programs. Backed by a recent $305 million Series F financing, Parabilis is entering an exciting phase of growth and execution. The Vice President, Medical Affairs Oncology is a member of the Development Leadership Team reporting to the Chief Medical Officer. This senior executive leader is accountable for the end-to-end design and execution of the Medical Affairs strategy across Parabilis portfolio, including Scientific Communications, Medical Education, Evidence Generation, Key Opinion Leader (KOL) Engagement, Publication Planning, and Medical Information. This role ensures scientific excellence and cross-functional integration across all development programs and builds a scalable Medical Affairs organization capable of supporting global, multi-indication growth.

Requirements

MD required; PharmD or PhD in a relevant biomedical discipline may be considered with commensurate experience
15+ years of progressive biopharmaceutical industry experience, with a minimum of 8 years in Medical Affairs with deep scientific expertise in oncology
Demonstrated success building and leading Medical Affairs organizations, including KOL engagement, evidence generation, and scientific communications
Experience standing up Medical Affairs capabilities in high-growth, clinical-stage biotech or pharmaceutical environments
Strong scientific credibility, executive leadership presence, and ability to engage effectively with both internal and external stakeholders
High emotional intelligence and track record of cross-functional influence across Development, Commercial, and Regulatory functions

Responsibilities

Define and execute the Medical Affairs Oncology strategy aligned with the clinical development roadmap and portfolio priorities.
Serve as a core member of the Development Leadership Team and contribute to broader Development governance and portfolio decision-making.
Support portfolio-level medical prioritization, lifecycle planning, and cross-indication strategy.
Build and sustain relationships with leading KOLs, academic medical centers, and cooperative groups relevant to Parabilis’ pipeline.
Design and oversee Medical Education programs that advance understanding of Parabilis’ science, novel mechanisms, and unmet need across tumor types.
Lead the development and execution of a robust evidence generation strategy, including investigator-initiated studies, real-world evidence, and health outcomes research.
Oversee development and execution of a comprehensive publication plan aligned with clinical milestones and regulatory timelines.
Build global medical affairs infrastructure to support multi-program, multi-regional growth.
Drive Medical Affairs KPIs and impact metrics in support of portfolio strategy and commercial readiness.
Lead scientific communications strategy to accurately and compellingly convey the differentiated profile of Parabilis’ Helicon™ platform and pipeline assets.
Oversee Medical Information function, ensuring timely, accurate, and compliant responses to healthcare professional inquiries.
Oversee the creation of high-quality medical education materials, slide decks, and scientific exchange resources.
Establish scalable medical affairs infrastructure to support launch readiness across tumor types and geographies.
Building trusted partnerships with advocacy organizations across Parabilis' specific tumor types.
Integrating the patient voice into MA strategy, trial design, and evidence generation.
Collaborating with patient communities on disease awareness and education.
Developing patient support programs to improve access, adherence, and trial participation ensuring all patients’ engagement is conducted with ethical rigor and full compliance.
Partner closely with Clinical Development, Regulatory Affairs, and New Product Planning to ensure scientific and medical alignment across the development and pre-commercialization continuum.
Support payer strategies by contributing to value dossiers, HEOR data packages.
Lead development and continuous improvement of Medical Affairs SOPs, governance frameworks, and compliance systems.
Ensure all Medical Affairs activities are executed in accordance with applicable regulations, industry codes, and Parabilis’ internal policies.
Build and mentor a high-performing Medical Affairs Oncology team with deep scientific expertise and strong cross-functional collaboration skills.
Establish clear accountability, performance metrics, and a culture of scientific rigor and integrity.
Foster a culture of collaboration, scientific curiosity, and patient-centricity across the Medical Affairs team.